

WEST

Generate Collection

Print

L4: Entry 3 of 4

File: EPAB

Feb 27, 2003

PUB-NO: WO003015822A1

DOCUMENT-IDENTIFIER: WO 3015822 A1

TITLE: 5-CNAC AS ORAL DELIVERY AGENT FOR PARATHYROID HORMONE FRAGMENTS

PUBN-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME

AZRIA, MOISE

BATEMAN, SIMON DAVID

COUNTRY

CH

US

ASSIGNEE-INFORMATION:

NAME

NOVARTIS AG

NOVARTIS PHARMA GMBH

AZRIA MOISE

BATEMAN SIMON DAVID

COUNTRY

CH

AT

CH

US

APPL-NO: EP00209181

APPL-DATE: August 16, 2002

PRIORITY-DATA: US31304801P (August 17, 2001)

INT-CL (IPC): A61 K 47/18; A61 K 38/29; A61 P 19/08; A61 P 19/10

EUR-CL (EPC): A61K009/48; A61K047/18

ABSTRACT:

CHG DATE=20030403 STATUS=O>Pharmaceutical compositions for the effective oral delivery of a parathyroid hormone, PTH, as well as methods for administration of the compositions are provided. Additionally, methods for stimulating new bone formation and treating and/or preventing osteoporosis are also provided.

WEST**End of Result Set**

Generate Collection

Print

L4: Entry 4 of 4

File: DWPI

Feb 27, 2003

DERWENT-ACC-NO: 2003-278518

DERWENT-WEEK: 200327

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Oral compositions comprising parathyroid hormone fragments and
N-(5-chlorosalicyloyl)-8-aminocaprylic acid, for treating e.g. osteoporosis

INVENTOR: AZRIA, M; BATEMAN, S D

PATENT-ASSIGNEE:

ASSIGNEE

NOVARTIS AG

NOVARTIS PHARMA GMBH

CODE

NOVS

NOVS

PRIORITY-DATA: 2001US-313048P (August 17, 2001)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

WO 2003015822 A1

February 27, 2003

E

015

A61K047/18

DESIGNATED-STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA
MD MK MN MX NO NZ OM PH PL PT RO RU SE SG SI SK TJ TM TN TR TT UA US UZ VC VN YU ZA
ZW AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

APPLICATION-DATA:

PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

WO2003015822A1

August 16, 2002

2002WO-EP09181

INT-CL (IPC): A61 K 38/29; A61 K 47/18; A61 P 19/08; A61 P 19/10

ABSTRACTED-PUB-NO: WO2003015822A

BASIC-ABSTRACT:

NOVELTY - A composition (C1) for oral delivery of parathyroid hormone comprising a
parathyroid hormone fragment selected from PTH (1-28) to PTH (1-41), and
N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for use of C1 for
stimulating new bone formation and treating or preventing osteoporosis. The PTH is
also recombinant PTH or recombinant hPTH.

ACTIVITY - Osteopathic.

Capsules were prepared comprising: (A) 800 micro g hPTH, or (B) 800 micro g hPTH and
400 mg 5-CNAC disodium salt, and administered orally to rhesus monkeys. Blood
samples were collected at intervals up to 6 hours after administration. Plasma hPTH
levels were determined by radioimmunoassay.

The hPTH plasma concentration following administration of capsule (A) was zero at all time points, compared with results for (B) at 0.25, 0.75, 1, 1.5, 3, 4 and 6 hours after dosing of 105, 482, 809, 206, 17, 0 and 0 pg/ml respectively.

MECHANISM OF ACTION - None given in the source material.

USE - For stimulating new bone formation, and treating or preventing osteoporosis (claimed), in humans and animals.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: ORAL COMPOSITION COMPRISE PARATHYROID HORMONE FRAGMENT N ACID TREAT OSTEOPOROSIS

DERWENT-CLASS: B05

CPI-CODES: B04-J04B; B04-J04B0E; B10-D03; B14-N01;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

M423 M431 M782 M905 P624 P625 P714 Q233

Specific Compounds

AA17MK AA17MT AA17MM

Chemical Indexing M1 *02*

Fragmentation Code

M417 M423 M431 M782 M905 P624 P625 P714 Q233

Specific Compounds

A00H1K A00H1T A00H1M

Chemical Indexing M1 *03*

Fragmentation Code

M423 M431 M782 M905 P624 P625 P714 Q233

Specific Compounds

AA17LK AA17LT AA17LM

Chemical Indexing M1 *04*

Fragmentation Code

D011 D601 F011 F012 F014 F019 F423 F521 F599 G010

G100 H1 H101 H183 H2 H211 H4 H405 H484 H5

H598 H599 H8 H9 J0 J014 J1 J173 J3 J311

J373 K0 L2 L250 L299 M210 M211 M271 M282 M311

M312 M313 M314 M315 M323 M331 M332 M333 M340 M342

M343 M349 M371 M381 M393 M423 M431 M511 M523 M531

M540 M782 M904 M905 P624 P625 P714 Q233

Specific Compounds

A05BLK A05BLT A05BLM

Chemical Indexing M2 *05*

Fragmentation Code

G015 G100 H4 H401 H441 H6 H602 H641 H8 J0

J012 J1 J171 J3 J331 M280 M315 M321 M332 M342

M381 M391 M414 M431 M510 M520 M531 M540 M782 M904

M905 P624 P625 P714 Q233

Specific Compounds

A5LM9K A5LM9T A5LM9M

Chemical Indexing M6 *06*

Fragmentation Code

M905 P624 P625 P714 Q233 R111 R280 R501 R520 R521

SECONDARY-ACC-NO: